Discovery and development of HIV-protease inhibitors - Wikipedia
HIV infects T cells that carry the CD4 antigen on their surface. When HIV infects its target cell it requires fusion of the ... The first reports of highly selective antagonists against the HIV protease were revealed in 1987. Phase I trials of saquinavir ... Tipranavir is a nonpeptidic HIV-1 protease inhibitor and reached the market in 2005. Unlike other HIV protease inhibitors on ... HIV protease inhibitors fit the active site of the HIV aspartic protease and were rationally designed utilizing knowledge of ...https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors
Subtypes of HIV - Wikipedia
... with the addition of CCR5 co-receptor antagonists and fusion inhibitors. Choice of initial and/or second-line therapy for HIV-2 ... HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in ... HIV superinfection HIV/AIDS research Discovery and development of CCR5 receptor antagonists History of HIV/AIDS Robertson DL, ... HIV/AIDS at Curlie (based on DMOZ) HIV Types at Avert.org 3D macromolecular structures of HIV-1 at the EM Data Bank(EMDB). ...https://en.wikipedia.org/wiki/Subtypes_of_HIV
CD4+ Cell Count, Lipid And Lipoprotein Levels In Hiv Patients On Drug Treatment
... between HIV-treatment with highly active antiretroviral therapy (HAART) and HIV-infection in particular. ... Protease inhibitors (PIs); integrase inhibitors; fusion inhibitors (or entry inhibitors) and CCR5 receptor antagonists . ... HIV-1 and HIV-2. HIV-1 is an enveloped RNA retrovirus which causes most HIV infections worldwide and HIV-2 which is found ... and HIV-infection in particular. The aim of this study was to find out correlations of HIV-treatment and HIV-infection with CAD ...https://scidoc.org/IJHR-2379-1586-04-102.php
Nanotechnology Approaches for Antiretroviral Drugs Delivery | Journal of AIDS and HIV Infections | Open Access Journals | Annex...
The advent of multidrug, highly active antiretroviral therapy (HAART), have increased the life span of HIV-infected patients. ... The development of effective drug delivery approaches for the treatment of AIDS and HIV infection is a global challenge. ... protease inhibitors (PIs); 5) fusion inhibitorsand 6) co-receptor antagonists. Moreover, FDA approved a combination of HIV ... 51 McGee B, Smith N, Aweeka F (2006) HIV pharmacology: Barriers to the eradication of HIV from the CNS. HIV Clin Trials 7: 142- ...http://www.annexpublishers.co/full-text/JAHI/1201/Nanotechnolog-Approaches-for-Antiretroviral-Drugs-Delivery.php
PRIME® Clinical Case Study: Management Considerations in a Patient Co-Infected with HIV and Pneumocystis carinii
... a newly-diagnosed HIV patient is hospitalized for Pneumocystis carinii co-infection. The case manager assigned to the case must ... fusion inhibitors (FIs), CCR5 antagonists ("entry inhibitors"), and integrase strand transfer inhibitors (INSTIs). The latter ... Development of novel therapies, such as the integrase strand transfer inhibitor (INSTI) raltegravir and the CCR5 antagonist ... It is these secondary infections which are the cause of morbidity in patients with HIV, not the HIV infection itself.2 The ...http://primeinc.org/casestudies/casemanager/study/821/Management_Considerations_in_a_Patient_Co-Infected_with_HIV_and_Pneumocystis_carinii
Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm | Retrovirology | Full Text
In spite of this diversity, the post-fusion structures of these proteins share a common trimeric hairpin motif in which the ... Recent structural studies revealed a stunning diversity of viral fusion proteins in their native state. ... Enveloped viruses encode specialized fusion proteins which promote the merger of viral and cell membranes, permitting the ... Recent functional work using various HIV fusion inhibitors provided new clues regarding the HIV entry process. ...https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-5-111
Viruses | Free Full-Text | Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV) | HTML
Due to marked similarity in genomic organization, virus structure, virus replication and disease pathogenesis of FIV and HIV, ... inhibition of fusion of the virus membrane with the cell membrane; (3) blockade of reverse transcription of viral genomic RNA ... Anti-retroviral drugs studied extensively in HIV infection have targeted different steps of the virus replication cycle: (1) ... infection of cats with FIV is a useful tool to study and develop novel drugs and vaccines for HIV. ...http://www.mdpi.com/1999-4915/4/5/708/htm
How does ilex 15 interact with HIV medications?
... reported amongst HIV-positive people include: low potassium levels,. ... integrase inhibitors, entry inhibitors, fusion inhibitors, CCR5 receptor antagonists, maturation inhibitors, etc. The drugs ... In HIV and AIDS How do HIV medications affect the progression of HIV? HIV treatments must be promptly administered to anyone ... In HIV and AIDS Can medical labs transmit HIV? Your question is unclear. Should a laboratory deal with the HIV virus there ...http://www.answers.com/Q/How_does_ilex_15_interact_with_HIV_medications
CCR5 interaction with HIV-1 Env contributes to Env-induced depletion of CD4 T cells in vitro and in vivo | Retrovirology | Full...
HIV-1 fusion inhibitor T20 was used as negative control to prevent HIV-1 infection. b Graphical summary showing kinetics of CD4 ... CCR5 antagonist TAK-779 protects CD4 T cells from R3A-induced bystander CD4 T cell depletion. Expression of R5-tropic HIV-1 Env ... HIV-1 fusion inhibitor T20 treatment was used as negative control. c Kinetics of CD4 T cell depletion by R3A versus R3A-5/6AA ... 3d, 5c), corresponding with previous reports that the R3A Env fusion activity  and other HIV-1 proteins can promote death ...https://retrovirology.biomedcentral.com/articles/10.1186/s12977-016-0255-z
Course Content - #64732: HIV/AIDS: Epidemic Update for Washington - NetCE
As the demographics of HIV infection evolve, both in the United States and around the world, it is clear that all healthcare ... and care of HIV-infected individuals should be obtained by all healthcare professionals. ... professionals in all practice settings will be involved to some extent with HIV infection. To be effective and provide ... Since the discovery of HIV, scientists have made major inroads in understanding modes of transmission, infectivity, and ...http://www.netce.com/coursecontent.php?courseid=1471
Flt-1 Intraceptor Induces the Unfolded Protein Response, Apoptotic Factors, and Regression of Murine Injury-Induced Corneal...
Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther. ... VEGF antagonists. Expert Opin Biol Ther. 2001;1:703-718. [CrossRef] [PubMed] ... receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. ... Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med. 1997;3:1110-1116. [CrossRef] [PubMed ...http://iovs.arvojournals.org/article.aspx?articleid=2125152
Bernd Meyer : Current : Publications : Organic Chemistry : Universität Hamburg
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Jan Münch, Ludger Ständker, ... Bioaffinity NMR spectroscopy: identification of an E-selectin antagonist in a substance mixture by transfer NOE. Dirk ... A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Axel T. Neffe, ... Synthesis and optimization of peptidomimetics as HIV entry inhibitors against the receptor protein CD4 using STD NMR and ligand ...https://www.chemie.uni-hamburg.de/oc/publikationen/Meyer_e.html
Ten years of highly active antiretroviral therapy for HIV infection | The Medical Journal of Australia
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: ... Only CCR5 antagonists have reached phase II/III clinical trials. Unfortunately, many CCR5 antagonists have unacceptable ... Fusion inhibitors. Enfuvirtide (T20) prevents fusion of the HIV viral membrane with the target cell membrane and therefore ... Entry inhibitors. This class interferes with binding of HIV to its target cell. These drugs specifically block CCR5 or CXCR4 ...https://www.mja.com.au/journal/2007/186/3/ten-years-highly-active-antiretroviral-therapy-hiv-infection
HIV Infection and AIDS: Practice Essentials, Background, Pathophysiology
HIV disease is caused by infection with HIV-1 or HIV-2, which are retroviruses in the Retrovir... ... HIV) is a blood-borne virus typically transmitted via sexual intercourse, shared intravenous drug paraphernalia, and mother-to- ... Antiretroviral Agent, Fusion Inhibitor. *Antiretroviral agent, CCR5 antagonist. *HIV, Entry Inhibitors. *Complete Regimen ... as the first rapid HIV test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 ...https://emedicine.medscape.com/article/211316-overview
Antiretroviral Therapy (ART) targeting HIV - ONA
FIs = Fusion Inhibitors. *. CCR5 Antagonists (also known as Chemokine (C-C motif) Receptor Blockers or HIV Co-Receptor Blockers ... i) HIV-antibody (if not on file, to confirm established HIV infection), CD4 cell count, HIV viral load. ... Protease inhibitor mutations. *. Mutations in the protease gene of HIV that render PIs ineffective may confer resistance to one ... Fusion inhibitors. *. enfuvirtide (T-20, ENF, Fuzeon®), infrequently used given that it has to be injected ...https://www.oncologynurseadvisor.com/hospital-medicine/antiretroviral-therapy-art-targeting-hiv/article/604514/
Inhibitors of Hepatitis C NS3 Protease - Patent application
CXCR4 antagonists (including but not limited to AMD-11070), fusion inhibitors (including but not limited to enfuvirtide ( ... invention with at least one of an HIV inhibitor, an HAV inhibitor and an HBV inhibitor. HIV inhibitors include agents ( ... Such agents can be selected from another anti-HCV agent; an HIV inhibitor; an HAV inhibitor; and an HBV inhibitor. Other ... HIV inhibitors include, but are not limited to: NRTIs (nucleoside or nucleotide reverse transcriptase inhibitors) ...http://www.patentsencyclopedia.com/app/20100087382
Investigating targets for a new class of anti-HIV drugs
... there is an urgent need for the discovery of a new class of anti-HIV drugs... ... prevent cell-to-cell fusion and block cell-associated transmission of HIV-1. ... They are now working to further develop more potent entry inhibitors from NBD-11021, with a higher selectivity index for pre- ... The team succeeded in transforming the full viral entry agonist NBD-556 to a full viral entry antagonist, NBD-11021, and ...http://researchfeatures.com/2016/11/01/investigating-targets-anti-hiv-drugs/
METHODS OF TREATING ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES WITH INHIBITORS OF MICROTUBULE AFFINITY REGULATING KINASE - THE...
In particular, the invention relates to methods of treating Alzheimer's disease and other tauopathies with inhibitors of mi ... MKI Fusions with the Cell-Penetrating Peptide HIV TAT. The cell-penetrating peptide, trans-activator of transcription (TAT) of ... antagonists (e.g., Namenda® (memantine)), and small molecule inhibitors of MARK (e.g., pyrazolo(1,5-a)pyrimidine and ... The terms "fusion protein," "fusion polypeptide," or "fusion peptide" as used herein refer to a fusion comprising a cell- ...http://www.freepatentsonline.com/y2016/0030510.html
Indian Patents. 246027:'DIAZAINDOLE-DICARBONYL -PIPERAZINYL COMPOUND'
HIV infection AIDs, protease inhibitor. T^ Hi). Fuzeon (or T-20). Roche / Trimeris. HIV infection AIDs, viral Fusion inhibitor ... Chemokine receptor antagonists as HIV entry inhibitors. Expert Opinion on Therapeutic Patents (2004), 14(2;, 251-255.. ... HIV infection, AIDS, ARC. (RT inhibitor). Novapren. Novaferon Labs, Inc. (Akron, OH). HIV inhibitor. Peptide T. Octapeptide. ... HIV infection, AIDS, ARC. Ritonavir. Abbott. HIV infection, AIDS, ARC. (protease inhibitor). Saquinavir. Hoffmann-LaRoche. HIV ...http://www.allindianpatents.com/patents/246027-diazaindole-dicarbonyl-piperazinyl-compound
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain...
We also discuss the effects of a TNF receptor biological fusion protein (etanercept) and the indirect anti-TNF agents dithio- ... Non-specific inhibitors of TNF. 3,6 Dithio-thalidomides. Thirty years after being removed from the market in 1961 because of ... Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 ... In 2011, the UCLA/Armagen group reported that a re-engineered version of etanercept, in which the IgG part of the fusion ...https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-016-0708-2
US20100287636A1 - Compositions and methods for inhibiting inducible t cell kinase (itk) and treating asthma and bronchial...
In one aspect, the invention provides inhibitors of ... The ITK protein inhibitors of the invention also can inhibit ... A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus ... This property prompted investigators to use Tat-fusion proteins as vehicles for the delivery of specific proteins or peptides ... Newer therapies at various stages of development include antagonists of receptors that are involved in the adhesion of ...https://patents.google.com/patent/US20100287636/en?oq=Compositions+and+methods+for+inhibiting+inducible+T+cell+Kinase+%28ITK%29+and+treating+asthma+and+bronchial+inflammations
CA2150249A1 - Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof ...
... or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-.alpha./LT-.beta. complex may be delivered to tumor ... makes a given cell a good target for HIV. proliferation.. A role for TNF has been proposed in enhancing HIV proliferation [L. ... Treatment of follicular lymphomas using inhibitors of the LT pathway CN1678625A (en) 2002-07-01. 2005-10-05. 比奥根艾迪克Ma公司. ... Compositions comprising variant LT-B-R-IG fusion proteins EP2073833A2 (en) 2006-10-20. 2009-07-01. Biogen Idec MA Inc.. ...https://patents.google.com/patent/CA2150249A1/en
Patent US5668149 - Inhibition of human immunodeficiency virus-1 infectivity in human cells - Google Patents
The methods comprise contacting human cells infected with HIV-1, with certain quinolinyl and acridinyl derivatives, including ... Methods are disclosed for inhibiting the infectivity of HIV-1 in human cells. ... fusion inhibitors, and CD4-GP120 binding inhibitors. US7851600. 16 Oct 2006. 14 Dec 2010. Progenics Pharmaceuticals Inc.. Anti- ... infection through the administration of CCR5 chemokine receptor antagonists. ...http://www.google.ca/patents/US5668149
Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry | Virology Journal | Full Text
As a competitive inhibitor of heparin, suramin has been described to have anti-viral activity. We tested the activity of ... Endogenous CD317/Tetherin limits replication of HIV-1 and murine leukemia virus in rodent cells and is resistant to antagonists ... E2 mediates cell attachment and E1 is a class II viral fusion protein . EBOV cell entry is mediated by a single envelope GP ... a multi-ion channel inhibitor and adrenoceptor antagonist, is a potent inhibitor of EBOV cell entry at concentrations reported ...https://virologyj.biomedcentral.com/articles/10.1186/s12985-016-0607-2
US Patent # 9,687,547. T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines - Patents.com
The present invention concerns methods and compositions for treatment of HIV infection using a T20 expression vector, such as ... The T20 fusion inhibitor could potentially be used in combination with a different fusion inhibitor. HIV fusion inhibitors are ... Alto et al., "Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type ... a reverse transcriptase inhibitor, a fusion inhibitor, a protease inhibitor, an integrase inhibitor and an anti-HIV antibody. ...http://patents.com/us-9687547.html